Patents by Inventor Takashi Torashima

Takashi Torashima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized anti-HMGB1 antibody or antigen-binding fragment thereof
    Patent number: 9550825
    Abstract: The present invention provides a humanized anti-HMGB1 antibody which specifically binds to a sequence consisting of the C-terminal 8 amino acid residues (EEEDDDDE) of HMGB1 protein and is effective for treatment or prevention of various inflammatory diseases related to this protein, as well as an antigen-binding fragment thereof. The present invention also provides a pharmaceutical composition comprising such an antibody or antigen-binding fragment thereof.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: January 24, 2017
    Assignees: EVEC INC., NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Kenzo Takada, Takashi Torashima, Masahiro Nishibori
  • HUMANIZED ANTl-HMGB1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
    Publication number: 20150361164
    Abstract: The present invention provides a humanized anti-HMGB1 antibody which specifically binds to a sequence consisting of the C-terminal 8 amino acid residues (EEEDDDDE) of HMGB1 protein and is effective for treatment or prevention of various inflammatory diseases related to this protein, as well as an antigen-binding fragment thereof. The present invention also provides a pharmaceutical composition comprising such an antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: December 6, 2013
    Publication date: December 17, 2015
    Inventors: Kenzo TAKADA, Takashi TORASHIMA, Masahiro NISHIBORl
  • HUMAN ANTIBODY SPECIFIC TO TOXIN PRODUCED FROM CLOSTRIDIUM DIFFICILE, OR ANTIGEN-BINDING FRAGMENT THEREOF
    Publication number: 20150259402
    Abstract: The present invention provides novel human-derived monoclonal antibodies specifically binding to toxins produced by Clostridium difficile (toxin A and toxin B), respectively, and having excellent neutralizing activity, and antigen-binding fragments thereof. The present invention also provides a pharmaceutical composition for the treatment of Clostridium difficile infection comprising any of the antibodies or antigen-binding fragments thereof.
    Type: Application
    Filed: October 18, 2013
    Publication date: September 17, 2015
    Inventors: Kenzo Takada, Masahiro Watanabe, Takashi Torashima
  • Purkinje cell-tropic viral vector
    Patent number: 8912315
    Abstract: The present invention relates to a Purkinje cell-tropic viral vector in which a modified L7 promoter and a therapeutic gene are operably linked to a virus-based plasmid vector.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: December 16, 2014
    Assignee: Japan Science and Technology Agency
    Inventors: Hirokazu Hirai, Takashi Torashima
  • Monoclonal antibody capable of binding to specific discontinuous epitope occurring in AD1 region of human cytomegalovirus GB glycoprotein, and antigen-binding fragment thereof
    Patent number: 8492529
    Abstract: The present invention provides a pharmaceutical composition for human cytomegalovirus HCMV causative of various disease states, the composition comprising a monoclonal antibody and an antigen-binding fragment thereof that specifically binds to the AD1 region of glycoprotein gB and that has excellent neutralizing capacity. The present invention provides: a monoclonal antibody and an antigen-binding fragment thereof having an excellent neutralizing capacity and cell-to-cell infection blocking capacity and specifically binding to a discontinuous sequence occurring in the HCMV AD1 region; a pharmaceutical composition comprising the antibody or the fragment thereof; and the like.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: July 23, 2013
    Assignee: Evec Incorporated
    Inventors: Kenzo Takada, Rika Kurino, Takashi Torashima
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO SPECIFIC DISCONTINUOUS EPITOPE OCCURRING IN AD1 REGION OF HUMAN CYTOMEGALOVIRUS GB GLYCOPROTEIN, AND ANTIGEN-BINDING FRAGMENT THEREOF
    Publication number: 20120093810
    Abstract: The present invention provides a pharmaceutical composition for human cytomegalovirus HCMV causative of various disease states, the composition comprising a monoclonal antibody and an antigen-binding fragment thereof that specifically binds to the AD1 region of glycoprotein gB and that has excellent neutralizing capacity. The present invention provides: a monoclonal antibody and an antigen-binding fragment thereof having an excellent neutralizing capacity and cell-to-cell infection blocking capacity and specifically binding to a discontinuous sequence occurring in the HCMV AD1 region; a pharmaceutical composition comprising the antibody or the fragment thereof; and the like.
    Type: Application
    Filed: April 1, 2010
    Publication date: April 19, 2012
    Applicant: EVEC INCORPORATED
    Inventors: Kenzo Takada, Rika Kurino, Takashi Torashima
  • Purkinje Cell-Tropic Viral Vector
    Publication number: 20100146649
    Abstract: The present invention relates to a Purkinje cell-tropic viral vector in which a modified L7 promoter and a therapeutic gene are operably linked to a virus-based plasmid vector.
    Type: Application
    Filed: March 7, 2007
    Publication date: June 10, 2010
    Inventors: Hirokazu Hirai, Takashi Torashima